Search for content, post, videos
Advertisement

BioArctic and Eisai sign research evaluation agreement

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exerc
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.